Clinical Trial Update: Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating myeloablative conditioning with hyperfractionated total body irradiation plus thiotepa and fludarabine followed by allogeneic stem cell…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoblastic Lymphoma
• Myelodysplastic Syndrome
• Non-hodgkin Lymphoma
• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• Fludarabine (Fludarabine)
• Thiottepa (thiotepa)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Allogeneic Stem Cell Transplant, Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2017-03-10